BeyondSpring's shares rallied ahead of the opening bell after the biopharmaceutical company reported positive results among an Asian subset in a late-stage trial of its lung cancer treatment. In ...

MRD-negative status in first four heavily treated patients with "off the shelf" product ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

Immatics (IMTX) announced updated Phase 1a dose escalation data from its second-generation PRAME cell therapy, IMA203CD8, in heavily pre-treated ...

Qihan's QT-019B program is supported by IND clearance for rSLE from both the US FDA and the China NMPA. The FDA has also granted Fast Track Designation for the SLE-ITP indication. Phase 1 enrollment ...

To detect estrogen and its metabolites in the ovarian-type stroma of pancreatic mucinous cystic neoplasm (MCN) tumors, researchers applied a novel liquid chromatography–tandem mass spectrometry (LC-MS ...

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

The European sperm market is booming, but are some donor's sperm being used to make too many babies?

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects ...

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement ...

Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...

Learn more about whether Nurix Therapeutics, Inc. or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.